Intellia Therapeutics, Inc. (NTLA) stock
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.78−0.08 (-0.81%)
Close on Nov 17, 2026Market cap $1.37BP/E –Yield –
Intellia Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Intellia Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $346.73M, down 22.2% year over year. For fiscal 2025 it was $388.86M, down 16.6% from the year before. Over ten years it grew 42.6% a year on average. The highest annual figure on record is $466.31M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $388.86M | -16.6% |
| FY2024 | Dec 31, 2024 | $466.31M | +7.2% |
| FY2023 | Dec 31, 2023 | $435.07M | +3.6% |
| FY2022 | Dec 31, 2022 | $419.98M | +82.8% |
| FY2021 | Dec 31, 2021 | $229.81M | +52.8% |
| FY2020 | Dec 31, 2020 | $150.41M | +38.7% |
| FY2019 | Dec 31, 2019 | $108.41M | +21.7% |
| FY2018 | Dec 31, 2018 | $89.12M | +31.7% |
| FY2017 | Dec 31, 2017 | $67.65M | +112.5% |
| FY2016 | Dec 31, 2016 | $31.84M | +185.0% |
| FY2015 | Dec 31, 2015 | $11.17M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $82.60M | -14.9% |
| Q1 FY2026 | Mar 31, 2026 | $80.74M | -25.5% |
| Q4 FY2025 | Dec 31, 2025 | $88.65M | -24.1% |
| Q3 FY2025 | Sep 30, 2025 | $94.75M | -23.2% |
| Q2 FY2025 | Jun 30, 2025 | $97.04M | -15.0% |
| Q1 FY2025 | Mar 31, 2025 | $108.43M | -3.1% |
| Q4 FY2024 | Dec 31, 2024 | $116.88M | +7.2% |
| Q3 FY2024 | Sep 30, 2024 | $123.38M | +8.5% |
| Q2 FY2024 | Jun 30, 2024 | $114.21M | -0.9% |
| Q1 FY2024 | Mar 31, 2024 | $111.85M | +15.2% |
| Q4 FY2023 | Dec 31, 2023 | $108.98M | +8.9% |
| Q3 FY2023 | Sep 30, 2023 | $113.70M | +17.6% |
| Q2 FY2023 | Jun 30, 2023 | $115.28M | +27.8% |
| Q1 FY2023 | Mar 31, 2023 | $97.12M | -27.0% |
| Q4 FY2022 | Dec 31, 2022 | $100.03M | +40.6% |
| Q3 FY2022 | Sep 30, 2022 | $96.65M | +59.8% |
| Q2 FY2022 | Jun 30, 2022 | $90.20M | +53.2% |
| Q1 FY2022 | Mar 31, 2022 | $133.10M | +238.9% |
| Q4 FY2021 | Dec 31, 2021 | $71.16M | +86.1% |
| Q3 FY2021 | Sep 30, 2021 | $60.49M | +52.1% |
| Q2 FY2021 | Jun 30, 2021 | $58.88M | +55.9% |
| Q1 FY2021 | Mar 31, 2021 | $39.28M | +13.4% |
| Q4 FY2020 | Dec 31, 2020 | $38.23M | +20.5% |
| Q3 FY2020 | Sep 30, 2020 | $39.76M | +44.5% |
| Q2 FY2020 | Jun 30, 2020 | $37.77M | +48.4% |
| Q1 FY2020 | Mar 31, 2020 | $34.65M | +46.1% |
| Q4 FY2019 | Dec 31, 2019 | $31.73M | +59.3% |
| Q3 FY2019 | Sep 30, 2019 | $27.51M | +18.4% |
| Q2 FY2019 | Jun 30, 2019 | $25.46M | +8.5% |
| Q1 FY2019 | Mar 31, 2019 | $23.71M | +5.4% |
| Q4 FY2018 | Dec 31, 2018 | $19.92M | -5.9% |
| Q3 FY2018 | Sep 30, 2018 | $23.24M | +32.9% |
| Q2 FY2018 | Jun 30, 2018 | $23.47M | +50.8% |
| Q1 FY2018 | Mar 31, 2018 | $22.49M | +67.5% |
| Q4 FY2017 | Dec 31, 2017 | $21.17M | +86.8% |
| Q3 FY2017 | Sep 30, 2017 | $17.48M | +122.4% |
| Q2 FY2017 | Jun 30, 2017 | $15.57M | – |
| Q1 FY2017 | Mar 31, 2017 | $13.43M | – |
| Q4 FY2016 | Dec 31, 2016 | $11.33M | – |
| Q3 FY2016 | Sep 30, 2016 | $7.86M | – |
See a number that looks wrong?